Esperion Therapeutics, Inc. (ESPR)
USD 1.18
(-4.47%)
USD 1.18
(-4.47%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 205.79 Million USD | -17.0% |
| 2022 | 247.93 Million USD | -35.02% |
| 2021 | 381.59 Million USD | 8.02% |
| 2020 | 353.25 Million USD | 64.73% |
| 2019 | 214.44 Million USD | 49.49% |
| 2018 | 143.45 Million USD | -48.37% |
| 2017 | 277.83 Million USD | 13.3% |
| 2016 | 245.21 Million USD | -17.04% |
| 2015 | 295.57 Million USD | 106.2% |
| 2014 | 143.34 Million USD | 83.08% |
| 2013 | 78.29 Million USD | 970.69% |
| 2012 | 7.31 Million USD | 235.47% |
| 2011 | 2.17 Million USD | 0.0% |
| 2002 | 51.4 Million USD | -34.38% |
| 2001 | 78.34 Million USD | 0.59% |
| 2000 | 77.87 Million USD | 873.6% |
| 1999 | 7.99 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 352.31 Million USD | -5.56% |
| 2024 Q1 | 373.06 Million USD | 81.28% |
| 2023 Q3 | 221.3 Million USD | -5.68% |
| 2023 FY | 205.79 Million USD | -17.0% |
| 2023 Q1 | 251.81 Million USD | 1.56% |
| 2023 Q4 | 205.79 Million USD | -7.01% |
| 2023 Q2 | 234.62 Million USD | -6.83% |
| 2022 Q1 | 342.85 Million USD | -10.15% |
| 2022 FY | 247.93 Million USD | -35.02% |
| 2022 Q2 | 303.98 Million USD | -11.34% |
| 2022 Q3 | 312.82 Million USD | 2.91% |
| 2022 Q4 | 247.93 Million USD | -20.74% |
| 2021 Q3 | 225.25 Million USD | -19.68% |
| 2021 Q4 | 381.59 Million USD | 69.4% |
| 2021 Q2 | 280.46 Million USD | 0.67% |
| 2021 FY | 381.59 Million USD | 8.02% |
| 2021 Q1 | 278.6 Million USD | -21.13% |
| 2020 Q2 | 330.35 Million USD | 83.89% |
| 2020 Q1 | 179.64 Million USD | -16.23% |
| 2020 Q3 | 250.96 Million USD | -24.03% |
| 2020 Q4 | 353.25 Million USD | 40.76% |
| 2020 FY | 353.25 Million USD | 64.73% |
| 2019 FY | 214.44 Million USD | 49.49% |
| 2019 Q2 | 308.81 Million USD | 30.59% |
| 2019 Q4 | 214.44 Million USD | -15.99% |
| 2019 Q3 | 255.27 Million USD | -17.34% |
| 2019 Q1 | 236.48 Million USD | 64.85% |
| 2018 Q4 | 143.45 Million USD | -17.57% |
| 2018 FY | 143.45 Million USD | -48.37% |
| 2018 Q3 | 174.03 Million USD | -17.47% |
| 2018 Q2 | 210.88 Million USD | -13.64% |
| 2018 Q1 | 244.18 Million USD | -12.11% |
| 2017 Q2 | 185.24 Million USD | -13.69% |
| 2017 FY | 277.83 Million USD | 13.3% |
| 2017 Q4 | 277.83 Million USD | -11.26% |
| 2017 Q3 | 313.09 Million USD | 69.02% |
| 2017 Q1 | 214.61 Million USD | -12.48% |
| 2016 FY | 245.21 Million USD | -17.04% |
| 2016 Q1 | 286.03 Million USD | -3.23% |
| 2016 Q2 | 277.46 Million USD | -3.0% |
| 2016 Q3 | 263.79 Million USD | -4.93% |
| 2016 Q4 | 245.21 Million USD | -7.04% |
| 2015 Q4 | 295.57 Million USD | -3.53% |
| 2015 FY | 295.57 Million USD | 106.2% |
| 2015 Q1 | 325.22 Million USD | 126.88% |
| 2015 Q2 | 315.95 Million USD | -2.85% |
| 2015 Q3 | 306.39 Million USD | -3.03% |
| 2014 Q4 | 143.34 Million USD | 136.81% |
| 2014 Q2 | 69.28 Million USD | -1.33% |
| 2014 FY | 143.34 Million USD | 83.08% |
| 2014 Q1 | 70.22 Million USD | -10.31% |
| 2014 Q3 | 60.53 Million USD | -12.64% |
| 2013 Q1 | 22.26 Million USD | 204.48% |
| 2013 FY | 78.29 Million USD | 970.69% |
| 2013 Q4 | 78.29 Million USD | -9.57% |
| 2013 Q3 | 86.57 Million USD | 343.2% |
| 2013 Q2 | 19.53 Million USD | -12.27% |
| 2012 FY | 7.31 Million USD | 235.47% |
| 2012 Q4 | 7.31 Million USD | 0.0% |
| 2011 FY | 2.17 Million USD | 0.0% |
| 2003 Q1 | 44.27 Million USD | -13.88% |
| 2003 Q2 | 38.15 Million USD | -13.82% |
| 2003 Q3 | 99.43 Million USD | 160.61% |
| 2002 Q3 | 57.08 Million USD | -11.22% |
| 2002 Q2 | 64.3 Million USD | -10.96% |
| 2002 Q4 | 51.4 Million USD | -9.95% |
| 2002 FY | 51.4 Million USD | -34.38% |
| 2002 Q1 | 72.22 Million USD | -7.81% |
| 2001 Q1 | 72.39 Million USD | -7.04% |
| 2001 Q2 | 68.28 Million USD | -5.69% |
| 2001 Q3 | 84.96 Million USD | 24.43% |
| 2001 Q4 | 78.34 Million USD | -7.8% |
| 2001 FY | 78.34 Million USD | 0.59% |
| 2000 Q3 | 82.87 Million USD | 220.25% |
| 2000 Q1 | 30.48 Million USD | 0.0% |
| 2000 FY | 77.87 Million USD | 873.6% |
| 2000 Q2 | 25.87 Million USD | -15.13% |
| 2000 Q4 | 77.87 Million USD | -6.03% |
| 1999 FY | 7.99 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Cosmos Health Inc. | 66.29 Million USD | -210.422% |
| Safety Shot Inc | 12.7 Million USD | -1519.27% |
| Bright Green Corporation | 17.4 Million USD | -1082.529% |
| Embecta Corp. | 1.21 Billion USD | 83.054% |
| ANI Pharmaceuticals, Inc. | 904.42 Million USD | 77.246% |
| Aquestive Therapeutics, Inc. | 57.41 Million USD | -258.417% |
| Collegium Pharmaceutical, Inc. | 1.14 Billion USD | 82.0% |
| Dynavax Technologies Corporation | 997.09 Million USD | 79.36% |
| Intra-Cellular Therapies, Inc. | 728.29 Million USD | 71.743% |
| Pacira BioSciences, Inc. | 1.57 Billion USD | 86.928% |
| PainReform Ltd. | 9.93 Million USD | -1972.467% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | -652.537% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | -652.537% |
| SCYNEXIS, Inc. | 128.41 Million USD | -60.262% |
| China SXT Pharmaceuticals, Inc. | 23.12 Million USD | -789.849% |
| Journey Medical Corporation | 76.84 Million USD | -167.793% |
| Alpha Teknova, Inc. | 128.58 Million USD | -60.044% |
| Procaps Group, S.A. | 460.18 Million USD | 55.28% |
| Theratechnologies Inc. | 77.76 Million USD | -164.625% |
| Harrow Health, Inc. | 311.75 Million USD | 33.988% |
| Sonoma Pharmaceuticals, Inc. | 14.89 Million USD | -1281.83% |
| Biofrontera Inc. | 27.93 Million USD | -636.775% |
| DURECT Corporation | 45.18 Million USD | -355.412% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | 85.394% |
| Cronos Group Inc. | 1.13 Billion USD | 81.856% |
| OptiNose, Inc. | 107.72 Million USD | -91.031% |
| Ironwood Pharmaceuticals, Inc. | 471.07 Million USD | 56.313% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -267.828% |
| RedHill Biopharma Ltd. | 23.04 Million USD | -792.935% |
| Organogenesis Holdings Inc. | 460.02 Million USD | 55.264% |
| Guardion Health Sciences, Inc. | 11.91 Million USD | -1626.741% |
| Cumberland Pharmaceuticals Inc. | 81.77 Million USD | -151.658% |
| Radius Health, Inc. | 1.71 Billion USD | 88.007% |
| Universe Pharmaceuticals INC | 53.28 Million USD | -286.203% |
| ProPhase Labs, Inc. | 91.92 Million USD | -123.869% |
| Phibro Animal Health Corporation | 982.18 Million USD | 79.047% |
| Procaps Group S.A. | 460.18 Million USD | 55.28% |
| Alvotech | 950.09 Million USD | 78.339% |
| TherapeuticsMD, Inc. | 43.3 Million USD | -375.181% |
| Viatris Inc. | 47.68 Billion USD | 99.568% |
| Rockwell Medical, Inc. | 52.17 Million USD | -294.449% |
| Aytu BioPharma, Inc. | 118.09 Million USD | -74.263% |
| SIGA Technologies, Inc. | 254.83 Million USD | 19.244% |
| Tilray Brands, Inc. | 4.33 Billion USD | 95.253% |
| Lifecore Biomedical, Inc. | 273.7 Million USD | 24.81% |
| Shineco, Inc. | 84.17 Million USD | -144.473% |
| PetIQ, Inc. | 868.22 Million USD | 76.297% |
| Regencell Bioscience Holdings Limited | 8.43 Million USD | -2338.858% |
| Incannex Healthcare Limited | 17.04 Million USD | -1107.227% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 93.671% |
| Alimera Sciences, Inc. | 153.52 Million USD | -34.048% |
| Silver Spike Investment Corp. | 88.57 Million USD | -132.338% |
| Assertio Holdings, Inc. | 286.41 Million USD | 28.149% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.95 Million USD | -3357.747% |
| Petros Pharmaceuticals, Inc. | 33.79 Million USD | -508.94% |
| Clever Leaves Holdings Inc. | 31.24 Million USD | -558.695% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -1453.466% |
| Avadel Pharmaceuticals plc | 261.12 Million USD | 21.189% |
| Hempacco Co., Inc. | 18.04 Million USD | -1040.581% |
| Talphera, Inc. | 20.39 Million USD | -909.051% |
| Alvotech | 950.09 Million USD | 78.339% |
| Eagle Pharmaceuticals, Inc. | 406.16 Million USD | 49.331% |
| Lantheus Holdings, Inc. | 1.65 Billion USD | 87.536% |
| Currenc Group, Inc. | 141.49 Million USD | -45.449% |
| Kamada Ltd. | 351.96 Million USD | 41.53% |
| Indivior PLC | 1.95 Billion USD | 89.453% |
| Evoke Pharma, Inc. | 7.06 Million USD | -2811.433% |
| Flora Growth Corp. | 23.62 Million USD | -771.057% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -1453.466% |
| Evolus, Inc. | 188.99 Million USD | -8.888% |
| HUTCHMED (China) Limited | 1.27 Billion USD | 83.919% |
| Amphastar Pharmaceuticals, Inc. | 1.51 Billion USD | 86.397% |
| Akanda Corp. | 8.83 Million USD | -2228.011% |